Detalles de la búsqueda
1.
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
Oncologist;
29(4): 342-349, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38207008
2.
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Cancer;
129(16): 2479-2490, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37185873
3.
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
Br J Haematol;
194(2): 309-318, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34145576
4.
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
Oncologist;
26(6): 523-532, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33594771
5.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat;
185(3): 697-707, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159633
6.
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
Acta Haematol;
142(4): 224-232, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31336367
7.
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
Blood;
127(12): 1551-8, 2016 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26755712
8.
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.
Am J Hematol;
93(8): 1074-1081, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29905379
9.
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Br J Haematol;
172(3): 384-91, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26577691
10.
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N Engl J Med;
366(12): 1079-89, 2012 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417203
11.
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Blood;
121(24): 4917-24, 2013 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23641016
12.
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
Br J Haematol;
166(3): 352-9, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24712482
13.
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Br J Haematol;
167(1): 62-8, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24995683
14.
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Breast Cancer Res Treat;
144(2): 321-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24487691
15.
Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70.
Cytometry A;
85(9): 798-808, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24845539
16.
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Blood;
120(11): 2297-306, 2012 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-22855599
17.
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.
Haematologica;
104(4): e147-e150, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30467203
18.
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
Blood;
117(20): 5306-13, 2011 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-21415269
19.
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Blood Adv;
7(19): 5941-5953, 2023 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37267439
20.
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
Breast Cancer Res;
14(6): R143, 2012 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23127292